FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138372232> ?p ?o ?g. }

• W2138372232 endingPage "S293" @default.
• W2138372232 startingPage "S292" @default.
• W2138372232 abstract "To report our initial clinical experience of radio-embolization, in which patients with liver metastasis were treated with intrahepatic Yttrium-90 microsphere through the hepatic arterial circulation. Data from 20 SIR-Spheres® Yttrium-90 microsphere radio-embolization procedures were reviewed. Patients received no antineoplastic therapy 4 weeks prior to or following the procedure. Ages ranged from 35 to 87 years. Pre-treatment hepatic angiogram confirmed anatomy, and embolization of the necessary arteries was performed. The primary tumor was neuroendocrine in 50% and other primary sites in 50%. Pretreatment scans were performed to ensure no excess lung shunting. The entire liver was treated in 75%, the right or left lobe selectively in 25%. Volume of liver treated ranged from 223–2630 (mean, 1378 cc). The range of dose delivered was 0.56–1.61 GBq. Radiographic response was evaluated with CT approximately 4 weeks following treatment. Follow-up ranged from 5–10 months. The treated dose was within 11% of the intended prescribed dose in all but one patient who developed static flow and received 41% of the prescribed dose. In all but a single patient, arterial flow slowed but did not reach stasis. The majority of patients had minimal side effects. The CTC V 3.0 grade 1 adverse events included 35% fatigue, 25% anorexia, 25% nausea, 20% abdominal pain and 10% vomiting. One patient had symptoms which lasted more than 1 week following treatment. Of the evaluable patients, radiographic tumor response has been seen in 71% at 4 weeks following treatment. Two patients have shown progression of disease and both have died within 3 months of treatment. Radiographic response has consisted of lesion necrosis, decrease in vascularity and decrease attenuation of the lesions. Those patients with radiographic response have also been found to have normal or stabilized liver function tests following treatment. No new liver lesions were identified in patients with radiographic response (Figure). Our initial clinical experience with Yttrium-90 radio-embolization for selected patients with liver metastasis has been encouraging. Radiographic response has been seen in 71% of patients with acceptable acute toxicity. Further evaluation with longer follow-up will help clarify the benefit of this novel treatment." @default.
• W2138372232 created "2016-06-24" @default.
• W2138372232 creator A5026686360 @default.
• W2138372232 creator A5030754323 @default.
• W2138372232 creator A5042478985 @default.
• W2138372232 creator A5045829589 @default.
• W2138372232 creator A5048589047 @default.
• W2138372232 creator A5083323180 @default.
• W2138372232 date "2007-11-01" @default.
• W2138372232 modified "2023-09-24" @default.
• W2138372232 title "An Initial Experience of Yttrium-90 Microsphere Radio-embolization in Liver Metastasis" @default.
• W2138372232 doi "https://doi.org/10.1016/j.ijrobp.2007.07.1335" @default.
• W2138372232 hasPublicationYear "2007" @default.
• W2138372232 type Work @default.
• W2138372232 sameAs 2138372232 @default.
• W2138372232 citedByCount "0" @default.
• W2138372232 crossrefType "journal-article" @default.
• W2138372232 hasAuthorship W2138372232A5026686360 @default.
• W2138372232 hasAuthorship W2138372232A5030754323 @default.
• W2138372232 hasAuthorship W2138372232A5042478985 @default.
• W2138372232 hasAuthorship W2138372232A5045829589 @default.
• W2138372232 hasAuthorship W2138372232A5048589047 @default.
• W2138372232 hasAuthorship W2138372232A5083323180 @default.
• W2138372232 hasConcept C121608353 @default.
• W2138372232 hasConcept C126322002 @default.
• W2138372232 hasConcept C126838900 @default.
• W2138372232 hasConcept C141071460 @default.
• W2138372232 hasConcept C197934379 @default.
• W2138372232 hasConcept C2776035437 @default.
• W2138372232 hasConcept C2778654693 @default.
• W2138372232 hasConcept C2779013556 @default.
• W2138372232 hasConcept C2780580376 @default.
• W2138372232 hasConcept C2780852908 @default.
• W2138372232 hasConcept C2989005 @default.
• W2138372232 hasConcept C71924100 @default.
• W2138372232 hasConceptScore W2138372232C121608353 @default.
• W2138372232 hasConceptScore W2138372232C126322002 @default.
• W2138372232 hasConceptScore W2138372232C126838900 @default.
• W2138372232 hasConceptScore W2138372232C141071460 @default.
• W2138372232 hasConceptScore W2138372232C197934379 @default.
• W2138372232 hasConceptScore W2138372232C2776035437 @default.
• W2138372232 hasConceptScore W2138372232C2778654693 @default.
• W2138372232 hasConceptScore W2138372232C2779013556 @default.
• W2138372232 hasConceptScore W2138372232C2780580376 @default.
• W2138372232 hasConceptScore W2138372232C2780852908 @default.
• W2138372232 hasConceptScore W2138372232C2989005 @default.
• W2138372232 hasConceptScore W2138372232C71924100 @default.
• W2138372232 hasIssue "3" @default.
• W2138372232 hasLocation W21383722321 @default.
• W2138372232 hasOpenAccess W2138372232 @default.
• W2138372232 hasPrimaryLocation W21383722321 @default.
• W2138372232 hasRelatedWork W1504204244 @default.
• W2138372232 hasRelatedWork W2156337883 @default.
• W2138372232 hasRelatedWork W2365756910 @default.
• W2138372232 hasRelatedWork W2391063887 @default.
• W2138372232 hasRelatedWork W2411143177 @default.
• W2138372232 hasRelatedWork W2418827130 @default.
• W2138372232 hasRelatedWork W2604052601 @default.
• W2138372232 hasRelatedWork W2966353290 @default.
• W2138372232 hasRelatedWork W2992708582 @default.
• W2138372232 hasRelatedWork W3031611473 @default.
• W2138372232 hasVolume "69" @default.
• W2138372232 isParatext "false" @default.
• W2138372232 isRetracted "false" @default.
• W2138372232 magId "2138372232" @default.
• W2138372232 workType "article" @default.